Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Update

Cellebrite DI Ltd. (NASDAQ:CLBT) saw a significant decline in short interest during the month of January. As of January 30th, there was short interest totaling 4,933,415 shares, a decline of 17.0% from the January 15th total of 5,947,018 shares. Based on an average trading volume of 1,951,160 shares, the short-interest ratio is currently 2.5 days. Currently, 2.2% of the shares of the stock are sold short. Currently, 2.2% of the shares of the stock are sold short. Based on an average trading volume of 1,951,160 shares, the short-interest ratio is currently 2.5 days.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CLBT shares. Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Bank of America lifted their target price on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Finally, Needham & Company LLC dropped their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Cellebrite DI has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Institutional Investors Weigh In On Cellebrite DI

Several large investors have recently bought and sold shares of CLBT. Voss Capital LP boosted its position in shares of Cellebrite DI by 18.9% during the fourth quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock worth $145,142,000 after purchasing an additional 1,277,300 shares in the last quarter. Invesco Ltd. raised its stake in Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after buying an additional 2,054,644 shares during the period. Pertento Partners LLP lifted its holdings in Cellebrite DI by 57.8% during the third quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after acquiring an additional 1,702,574 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its stake in Cellebrite DI by 17.1% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock valued at $62,608,000 after acquiring an additional 570,000 shares during the period. Finally, Cooper Creek Partners Management LLC acquired a new position in Cellebrite DI in the third quarter valued at about $55,999,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Up 6.9%

Shares of Cellebrite DI stock opened at $14.64 on Tuesday. The business has a fifty day simple moving average of $16.98 and a 200 day simple moving average of $17.02. The stock has a market cap of $3.51 billion, a PE ratio of 47.23, a price-to-earnings-growth ratio of 2.15 and a beta of 1.28. Cellebrite DI has a 12 month low of $13.10 and a 12 month high of $21.42.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14. The firm had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company’s quarterly revenue was up 28.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Analysts expect that Cellebrite DI will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.